Article
Distinct molecular subtypes of KRASG12C-mutant lung adenocarcinoma: Insights into clinical outcomes, tumour microenvironments and therapeutic strategies.
Clinical and translational medicine - 1 Oct 2025
Yang Haitang, Zhu Anshun, Niu Yongliang, Ma Wenyan, Xu Ke, Jia Yunxuan, Xu Weijiao, Zhao Baicheng, Zhang Enshuo, Jia Jiaying, Liang Shunqing, Dorn Patrick, Liu Gang, Peng Ren-Wang, Yao Feng
Abstract excerpt
BACKGROUND: KRASG12C is the most common KRAS mutation in lung adenocarcinoma (LUAD), yet clinical responses to KRASG12C-selective inhibitors (G12Ci) and immunotherapy remain variable. METHODS: Transcriptomic analysis of KRASG12C-mutant LUAD was performed using machine learning algorithms to classify molecular subtypes. Subtype-specific features, including genomic alterations, tumour microenvironment and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.